Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 10/20 | 0.32 |
| ▸ | CNR1 | P21554 | 6/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772643 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CNR2CNR1 | |
| SCHEMBL16162162 | 0.81 | CNR1 (0.43) | CNR2CNR1 | |
| SCHEMBL2773654 | 0.78 | KDM4E (0.43) | L3MBTL1CNR2CNR1LMNAMAPT | |
| SCHEMBL13238761 | 0.70 | RAB9A (0.36) | L3MBTL1HDAC9NPC1RAB9AMAPT | |
| SCHEMBL2774194 | 0.69 | L3MBTL1 (0.39) | L3MBTL1CNR2CNR1 | |
| SCHEMBL13156937 | 0.69 | CNR2 (0.45) | L3MBTL1NPC1RAB9ACNR2CNR1 | |
| SCHEMBL2773251 | 0.69 | KDM4E (0.43) | L3MBTL1CNR2CNR1LMNAMAPT | |
| SCHEMBL13157146 | 0.65 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL2774623 | 0.64 | MAPT (0.43) | L3MBTL1NPC1RAB9ACNR2CNR1 | |
| SCHEMBL496034 | 0.63 | CNR2 (0.49) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | OPRM1 4/4885L3MBTL1 4607/4885HDAC9 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.